275 related articles for article (PubMed ID: 27140309)
1. In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab.
Ueda S; Saeki T; Takeuchi H; Shigekawa T; Yamane T; Kuji I; Osaki A
Br J Cancer; 2016 May; 114(11):1212-8. PubMed ID: 27140309
[TBL] [Abstract][Full Text] [Related]
2. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
Cortes J; Montero AJ; Glück S
Cancer Treat Rev; 2012 Apr; 38(2):143-51. PubMed ID: 21550727
[TBL] [Abstract][Full Text] [Related]
3. Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer.
Kashiwagi S; Fukushima W; Asano Y; Goto W; Takada K; Noda S; Takashima T; Onoda N; Ohsawa M; Hirakawa K; Ohira M
BMC Cancer; 2017 Aug; 17(1):604. PubMed ID: 28859615
[TBL] [Abstract][Full Text] [Related]
4. Eribulin mesylate for the treatment of late-stage breast cancer.
Gourmelon C; Frenel JS; Campone M
Expert Opin Pharmacother; 2011 Dec; 12(18):2883-90. PubMed ID: 22087618
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma.
Emambux S; Italiano A
Expert Opin Pharmacother; 2017 Jun; 18(8):819-824. PubMed ID: 28468516
[TBL] [Abstract][Full Text] [Related]
6. Eribulin mesylate in breast cancer.
Verdaguer H; Morilla I; Urruticoechea A
Womens Health (Lond); 2013 Nov; 9(6):517-26. PubMed ID: 24161305
[TBL] [Abstract][Full Text] [Related]
7. [Two Cases in Which Eribulin Mesylate Was Effective for Taxane-Resistant Advanced Breast Cancer].
Adachi K; Suzuki S; Kubota H; Hara Y; Fujiwara A; Waga E; Hirano T; Enomoto K; Sakurai K; Makishima M; Koshinaga T
Gan To Kagaku Ryoho; 2017 Oct; 44(10):938-940. PubMed ID: 29066702
[TBL] [Abstract][Full Text] [Related]
8. Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators.
Inoue K; Ninomiya J; Saito T; Kimizuka K; Kurosumi M
BMC Cancer; 2018 Jun; 18(1):671. PubMed ID: 29925345
[TBL] [Abstract][Full Text] [Related]
9. Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
Aseyev O; Ribeiro JM; Cardoso F
Expert Opin Pharmacother; 2016; 17(4):589-600. PubMed ID: 26809667
[TBL] [Abstract][Full Text] [Related]
10. Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now?
Rugo HS; O'Shaughnessy JA; Perez EA
Clin Adv Hematol Oncol; 2011 Nov; 9(11):1-16. PubMed ID: 22355830
[TBL] [Abstract][Full Text] [Related]
11. [A Case of Recurrent Breast Cancer with Complete Response to Eribulin Monotherapy after Bevacizumab plus Paclitaxel Combination Therapy].
Higashi T; Ozawa K; Takagi S; Onodera Y; Yokoyama M; Mase K; Moriya T; Takeshita A; Mizutani M; Usuba O
Gan To Kagaku Ryoho; 2018 Jul; 45(7):1093-1095. PubMed ID: 30042279
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab Induces Acute Hypoxia and Cancer Progression in Patients with Refractory Breast Cancer: Multimodal Functional Imaging and Multiplex Cytokine Analysis.
Ueda S; Saeki T; Osaki A; Yamane T; Kuji I
Clin Cancer Res; 2017 Oct; 23(19):5769-5778. PubMed ID: 28679773
[No Abstract] [Full Text] [Related]
13. Validation of Systemic and Local Tumour Immune Response to Eribulin Chemotherapy in the Treatment of Breast Cancer.
Kashiwagi S; Asano Y; Goto W; Takada K; Morisaki T; Kouhashi R; Yabumoto A; Tanaka S; Takashima T; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2020 Jun; 40(6):3345-3354. PubMed ID: 32487630
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH
Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177
[TBL] [Abstract][Full Text] [Related]
15. Eribulin, a microtubule inhibitor for metastatic breast cancer.
Wilkes GM
Oncology (Williston Park); 2011 Feb; 25(2 Suppl Nurse Ed):46-8. PubMed ID: 25373284
[No Abstract] [Full Text] [Related]
16. Eribulin in advanced breast cancer: safety, efficacy and new perspectives.
Garrone O; Miraglio E; Vandone AM; Vanella P; Lingua D; Merlano MC
Future Oncol; 2017 Dec; 13(30):2759-2769. PubMed ID: 29219017
[TBL] [Abstract][Full Text] [Related]
17. Eribulin: rediscovering tubulin as an anticancer target.
Jimeno A
Clin Cancer Res; 2009 Jun; 15(12):3903-5. PubMed ID: 19509144
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
[TBL] [Abstract][Full Text] [Related]
19. Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.
Polastro L; Aftimos PG; Awada A
Expert Rev Anticancer Ther; 2014 Jun; 14(6):649-65. PubMed ID: 24852360
[TBL] [Abstract][Full Text] [Related]
20. Eribulin mesylate for the treatment of breast cancer.
Cigler T; Vahdat LT
Expert Opin Pharmacother; 2010 Jun; 11(9):1587-93. PubMed ID: 20450446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
